1. Cavero I, Galzin AM, Langer SZ, Lefevre-Borg F, Manoury P, Pimoule C (1984) Alfuzosin (SL 77.499), a new antihypertensive agent with a peripheral site of action: II. In vitro pharmacological studies. Br J Pharmacol 81: 14P
2. Cavero I, Lefevre-Borg F, Manoury P (1984) Alfuzosin (SL 77.499), a new antihypertensive agent with a peripheral site of action: I. In vivo pharmacological studies. Br J Pharmacol 81: 13P
3. Guinebault P, Colafranceschi C, Bianchetti G, Thenot JP, Maillard D, Thiercelin JF, Larribaud J, Morselli PL (1984) Absolute bioavailability of alfuzosin a new alpha1-post synaptic receptor antagonist, after oral and intravenous administration. In: Aiache JM, Hirtz J (eds) Experimental pharmacokinetics. Proceedings of the 2nd European Congress of Biopharmaceutics and Pharmacokinetics, Salamanca (24?27 April, 1984), vol II, pp 578?583
4. Leren P, Eide I, Foss OP, Helgeland A, Hjermann I, Holme I, Kjeldsen SE, Lund-Larsen PG (1984) Antihypertensive drugs and blood lipids: The Oslo study. Br J Clin Pharmacol 13: 441S-444S
5. Graham RM, Thornell RI, Gain JM, Bagnoli C, Oates FH, Stokes GS (1976) Prazosin: The first-dose phenomenon. Br Med J 273: 1293?1294